Postdoctoral Fellow in Immunology/Genetics

Organization
Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD)
Job Location
1090 Vienna
Austria
Benefits

We offer:

  • a challenging position in a meaningful, inspiring, international setting
  • an excellent work climate and the possibility to join our social activities
  • a competitive salary: This position is remunerated according to FWF personnel costs (http://www.fwf.ac.at/en/research-funding/personnel-costs)
Job Description

The Boztug Lab at LBI-RUD, the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases in Vienna, seeks to fill the open full-time position of a

 

POSTDOCTORAL FELLOW (reference code: #PD/KB16)

 

The focus of the group is on the identification of rare monogenic disorders of the immune system and hematopoiesis to explain pathophysiological manifestations in humans (Boztug K at al Nature Genet 2014, Willmann K et al Nature Commun 2014, Dobbs K et al New Engl J Med 2015). In the context of this work, the Boztug group applies a combination of state-of-the-art genetic and genomic technologies including next generation sequencing, and a wide range of cellular and molecular techniques to elucidate novel pathways important for immune system homeostasis.

The group works in a fully equipped molecular biology laboratory in a shared environment with cell culture, multi-color flow cytometry as well as all equipment needed for state-of-the-art genomic investigations such as SNP arrays and deep sequencing, which are immediately accessible in-house.

 

We are looking for a highly motivated and well-organized Postdoctoral Fellow to join one of the following projects:

Project 1: Deciphering the molecular basis of autoimmunity and autoinflammation

Due to their heterogeneity and prevalence, autoimmune diseases pose a major health problem to modern societies. We have recently identified several novel disease-causing genes in patients with model autoimmune disorders such as early-onset IBD (Glocker*, Kotlarz*, Boztug* et al NEJM 2009; Salzer et al JACI 2014) and early-onset SLE-like diseases (Salzer*, Santos-Valente* et al Blood 2013). This exciting project aims at identifying novel genes within a patient cohort of genetically undiagnosed autoimmune disorders by a variety of biochemical, immunological and imaging technologies to obtain molecular gene-to-phenotype relationships.

Project 2: Identifying and understanding novel types of combined immunodeficiency

Combined immunodeficiencies (CIDs) comprise a large proportion of primary immunodeficiencies. Recently our group has significantly contributed to the field by discovery and detailed molecular description of novel types of CID affecting NF-kB signaling and cellular motility, respectively (Willmann*, Klaver* et al Nature Commun 2014; Dobbs*, Dominguez-Conde* et al New Engl J Med 2015), however to date many CID etiologies still remain undefined, precluding precise treatment recommendations. The proposed project aims to identify novel genes using NGS technology to discover additional cellular pathways underlying CIDs on an ever-growing cohort of patient samples present in the lab.

Project 3: Dissecting molecular pathomechanisms of PIDs using small molecule screens

The translational value of research on PIDs lies in the ability to develop mechanism-based tailored treatment options often hindered by lack of knowledge about molecular pathways underlying the disease. The candidate will develop hypothesis-driven early drug discovery research for few carefully selected PID targets by performing genetic and small molecule screens using the state-of-the-art haploid cell and chemical screening platforms combined with a comprehensive drug library, all available in-house (in collaboration with CeMM PI Stefan Kubicek; e.g. Winter et al Nature Chem Biol 2014; Jae et al Science 2014). 

Requirements

Requirements and desired qualifications:

The successful candidate is a proactive and independent thinker with a strong background in one or more of the following disciplines: Immunology, Genetics, Medicine or Molecular Biology, and holds a PhD (respectively DVM/MD or equivalent) degree. The ideal candidate will have an excellent work ethic and very good communication skills. Enthusiasm, self-motivation, creativity as well as a proactive approach to solving problems and developing new ideas are highly desirable. We are looking for a candidate who is able to connect different scientific disciplines and think outside the box. The candidate should have at least one first author paper in a high impact factor journal (IF>10).

How to Apply

Applicants should please submit: A cover letter (describing your career goals and explaining why you are the ideal candidate for this position), a curriculum vitae and names and contact details of 2-3 referees, in a single PDF file to: [email protected] using the reference code #PD/KB16 in the header. Application deadline is 15th July 2016, or until the position is filled.

About Our Organization

The Institute:

The newly founded Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD) is directed by Kaan Boztug, a world-leading expert in primary immunodeficiency research, and is situated in a beautiful, bright, and perfectly designed building with outstanding design and state-of-the-art laboratories and technology platforms that is strategically located next to one of the world’s largest university hospitals in the heart of the city. The institute is deeply integrated with its renowned partner institutions, namely the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, the Medical University of Vienna, and the Children’s Cancer Research Institute of the St. Anna Children’s Hospital, and, therefore perfectly situated to benefit from strong translational research long established by leading-edge research groups.

For more information please visit: http://www.cemm.oeaw.ac.at/research/groups/kaan-boztug-adjunct-pi/

Institute homepage will be available shortly: http://rud.lbg.ac.at

Students whose classmates are interested in science are more likely to think about a career in science, technology, engineering, and mathematics, a new study says.

CNBC reports that the genetic counseling field is expected to grow as personalized medicine becomes more common.

Gladys Kong writes at Fortune that her STEM background has helped her as a CEO.

Social scientists report that the image of the 'lone scientist' might be deterring US students from STEM careers.